SI
NKTR icon

Sofinnova Investments’s Nektar Therapeutics NKTR Stock Holding History

Sofinnova Investments’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.9M Sell
471,763
-37,783
-7% -$2.76M 1.7% 22
2026
Q1 		$36.7M Buy
509,546
+70,916
+16% +$4.04M 1.39% 26
2025
Q4 		$18.5M Buy
438,630
+320,211
+270% +$17.9M 0.8% 36
2025
Q3 		$6.74M Buy
+118,419
New +$3.92M 0.37% 50

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sofinnova Investments's NKTR Position: Q2 2026 in Review

Sofinnova Investments reduced its Nektar Therapeutics (NKTR) stake by 7.4% in Q2 2026, selling an estimated $2.76M and leaving 471,763 shares worth $32.9M. The position accounts for 1.7% of the portfolio, ranked #22.

Sofinnova Investments first reported a position in NKTR in Q3 2025 and has held it in 4 quarters since. The position peaked at $36.7M in Q1 2026. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Sofinnova Investments held 471,763 shares of Nektar Therapeutics worth $32.9M as of Q2 2026.
  • Sofinnova Investments sold 37,783 Nektar Therapeutics shares in Q2 2026, an estimated $2.76M.
  • Nektar Therapeutics made up 1.7% of Sofinnova Investments's portfolio in Q2 2026, its #22 holding.
  • Sofinnova Investments first reported a position in Nektar Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Sofinnova Investments's Nektar Therapeutics position peaked at $36.7M in Q1 2026.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Sofinnova Investments's 13F filing for Q2 2026, filed 14 Aug 2026.